Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats
- PMID: 34259969
- DOI: 10.1007/s10620-021-07131-x
Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats
Abstract
Background: Since gut microbiota is involved in the pathogenesis of inflammatory bowel disease (IBD), antibiotics or probiotics may be attractive options for the treatment of IBD. Akkermansia muciniphila is expected as a next-generation probiotic for IBD, and OPS-2071 is a novel quinolone with potent antibacterial activity against Clostridioides difficile.
Aims: The aim of this study is to assess the potential of OPS-2071 as a gut microbiota modulator for IBD.
Methods: Minimum inhibitory concentrations of several bacteria in the human intestinal microbiota were determined. Microbiota changes in the feces were typed using metagenomic analysis after oral administration of OPS-2071 (100 mg/kg) twice a day to normal rats. The amounts of mucin were determined using the Fecal Mucin Assay Kit. The effects of OPS-2071 (1, 3, 10 mg/kg) twice a day on fecal symptoms and fecal microbiota were evaluated in a colitis rat model induced by free access to drinking water containing 3% dextran sulfate sodium for 10 days.
Results: OPS-2071 showed notably low antibacterial activity against only A. muciniphila in spite of higher antimicrobial activity against other strains of intestinal bacteria. OPS-2071 rapidly and dramatically increased the occupancy of A. muciniphila as well as the amount of mucin in the feces of normal rats. OPS-2071 (10 mg/kg) significantly suppressed the exacerbation of stool scores, especially the bloody stool score, with the increase in A. muciniphila occupancy.
Conclusions: OPS-2071 is expected to be a new therapeutic option for IBD as a gut microbiota modulator by significantly increasing A. muciniphila occupancy.
Keywords: Akkermansia; Dextran sulfate sodium induced colitis; Gut microbiota; Inflammatory bowel disease; OPS-2071; Ulcerative colitis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
The combination of Clostridium butyricum and Akkermansia muciniphila mitigates DSS-induced colitis and attenuates colitis-associated tumorigenesis by modulating gut microbiota and reducing CD8+ T cells in mice.mSystems. 2025 Feb 18;10(2):e0156724. doi: 10.1128/msystems.01567-24. Epub 2025 Jan 22. mSystems. 2025. PMID: 39840995 Free PMC article.
-
Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation.Microbiol Spectr. 2021 Oct 31;9(2):e0073021. doi: 10.1128/Spectrum.00730-21. Epub 2021 Oct 6. Microbiol Spectr. 2021. PMID: 34612661 Free PMC article.
-
Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice.Front Cell Infect Microbiol. 2019 Jul 5;9:239. doi: 10.3389/fcimb.2019.00239. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31334133 Free PMC article.
-
The potential of Akkermansia muciniphila in inflammatory bowel disease.Appl Microbiol Biotechnol. 2021 Aug;105(14-15):5785-5794. doi: 10.1007/s00253-021-11453-1. Epub 2021 Jul 27. Appl Microbiol Biotechnol. 2021. PMID: 34312713 Review.
-
The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives.Front Immunol. 2023 Jan 6;13:1089600. doi: 10.3389/fimmu.2022.1089600. eCollection 2022. Front Immunol. 2023. PMID: 36685588 Free PMC article. Review.
Cited by
-
Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.mBio. 2022 Aug 30;13(4):e0136422. doi: 10.1128/mbio.01364-22. Epub 2022 Aug 1. mBio. 2022. PMID: 35913161 Free PMC article.
-
Dietary Magnesium Alleviates Experimental Murine Colitis through Modulation of Gut Microbiota.Nutrients. 2021 Nov 23;13(12):4188. doi: 10.3390/nu13124188. Nutrients. 2021. PMID: 34959740 Free PMC article.
-
Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored.Int J Mol Sci. 2023 Jul 2;24(13):11004. doi: 10.3390/ijms241311004. Int J Mol Sci. 2023. PMID: 37446182 Free PMC article. Review.
-
Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases.Front Immunol. 2024 Mar 20;15:1370658. doi: 10.3389/fimmu.2024.1370658. eCollection 2024. Front Immunol. 2024. PMID: 38571945 Free PMC article. Review.
-
Health and Disease: Akkermansia muciniphila, the Shining Star of the Gut Flora.Research (Wash D C). 2023;6:0107. doi: 10.34133/research.0107. Epub 2023 Apr 3. Research (Wash D C). 2023. PMID: 37040299 Free PMC article.
References
-
- Kobayashi T, Siegmund B, Le Berre C et al. Ulcerative colitis. Nat Rev Dis Primers 2020;6:74. - DOI
-
- Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521–533. - DOI
-
- Guan QA. Comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019;2019:7247238. - DOI
-
- Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380:1590–1605. - DOI
-
- Ma C, Battat R, Dulai PS et al. Innovations in oral therapies for inflammatory bowel disease. Drugs 2019;79:1321–1335. - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources